




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Corrigendum

## Corrigendum to “Analytical and clinical comparison of Viasure (CerTest Biotec) and 2019-nCoV CDC (IDT) RT-qPCR kits for SARS-CoV2 diagnosis” [Virology volume (2021) 154–156]

Byron Freire-Paspuel<sup>a</sup>, Patricio Vega-Marino<sup>b</sup>, Alberto Velez<sup>b</sup>, Marilyn Cruz<sup>b</sup>, Franklin Perez<sup>c</sup>, Miguel Angel Garcia-Bereguain<sup>a,\*</sup>

<sup>a</sup> One Health Research Group, Universidad de Las Americas, Quito, Ecuador

<sup>b</sup> Agencia de Regulacion y Control de La Bioseguridad y Cuarentena para Galapagos, Puerto Ayora, Ecuador

<sup>c</sup> OneLabt, Santa Elena, Ecuador



1. On the introduction section. The sentence “Also, it was recently authorized for SARS-CoV2 diagnosis in Ecuador. However, it is not included on the list of FDA EUA kits (5) and only an evaluation study for Viasure SARS-CoV-2 RT-qPCR kit has been reported comparing to an automatized system like de Cobas 6800, besides the limited validation provided by manufacturer’s manual (6,7)”, m **must be replaced by this one**: “Also, it was recently authorized for SARS-CoV2 diagnosis in Ecuador. However, it is not included on the list of FDA EUA kits (5) and only a limited validation provided by the manufacturer is available; although there is a recent report evaluating the clinical performance for another Viasure SARS-CoV-2 kit targeting the S gene (6, 7).”
2. On the discussion section. The paragraph: “It came to our attention a recent study about the clinical performance of Viasure SARS-CoV-2 compared to Cobas 6800 system using a total number of 95

samples (6). The authors reported a lost of sensitivity of 30,9% for Viasure SARS-CoV-2 kit, with only 47 out of 68 positive samples detected. However, all the samples that failed to be positive for Viasure SARS-CoV-2 kit had viral loads over 2000 copies/mL of sample (6). Considering the viral loads frequency distribution for SARS-CoV-2 (11, 12), this study would have a bias toward ultra low viral loads below 2000 copies/mL as less than 10% of SARS-CoV-2 positive patients are expected to have those loads (11, 12)”, **has to be followed by this sentence one**: “Additionally, this Viasure SARS-CoV-2 S gene RT-PCR kit is different to the one evaluated in our study, as different gene targets are used, so the results among both studies are not comparable”.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.virol.2020.10.010>.

\* Corresponding author.

E-mail address: [magbereguain@gmail.com](mailto:magbereguain@gmail.com) (M.A. Garcia-Bereguain).

<https://doi.org/10.1016/j.virol.2020.12.019>

Available online 5 January 2021

0042-6822/© 2020 Elsevier Inc. This article is made available under the Elsevier license (<http://www.elsevier.com/open-access/userlicense/1.0/>).